Table 1 Routes to escape from targeted therapy in cancer
• Genetic variation | i. ‘Target’ segregated in sub-clones, not truncal |
ii. ‘Target’ mutated and impervious to drugs | |
• Epigenetic plasticity | i. Inhibited target bypassed by signal redundancy in network |
ii. Quiescent/dormant stem cells intrinsically resistant |